Business ❯ Finance ❯ Mergers and Acquisitions ❯ Pharmaceuticals

Oncology

Merck to Acquire Terns for $6.7 Billion to Add Promising Leukemia Drug

The small premium leaves room for rival offers.

Merck Ends Revolution Medicines Takeover Talks After Valuation Standoff